4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 1,300.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 1,820.00
  • 52 Week Low: 545.00
  • Currency: UK Pounds
  • Shares Issued: 15.48m
  • Volume: 2
  • Market Cap: £201.21m
  • Beta: 0.21

Largest Deals (365 days)

Show trades greater than:
Traded Action Notifier PriceAmountValue
15-Nov-24 Sell Heikki Lanckriet 1,325.00p 46,500 £616,125.00
15-Nov-24 Buy Heikki Lanckriet 1,325.00p 46,500 £616,125.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 1,300.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 1,820.00
52 Week Low 545.00
Volume 2
Shares Issued 15.48m
Market Cap £201.21m
Beta 0.21

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
25.57% below the market average25.57% below the market average25.57% below the market average25.57% below the market average25.57% below the market average
28.00% above the sector average28.00% above the sector average28.00% above the sector average28.00% above the sector average28.00% above the sector average
Price Trend
70.60% above the market average70.60% above the market average70.60% above the market average70.60% above the market average70.60% above the market average
95.92% above the sector average95.92% above the sector average95.92% above the sector average95.92% above the sector average95.92% above the sector average
Income Not Available
Growth
35.67% above the market average35.67% above the market average35.67% above the market average35.67% above the market average35.67% above the market average
35.29% above the sector average35.29% above the sector average35.29% above the sector average35.29% above the sector average35.29% above the sector average

4basebio Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
16:04 2 @ 1,310.00p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page